1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > EpiCast Report: Myasthenia Gravis - Epidemiology Forecast to 2024

EpiCast Report: Myasthenia Gravis - Epidemiology Forecast to 2024

  • June 2015
  • -
  • GlobalData
  • -
  • 37 pages

Summary

Table of Contents

Search Inside

EpiCast Report: Myasthenia Gravis - Epidemiology Forecast to 2024

Summary

Myasthenia gravis is an autoimmune disease that affects the nerves and muscles and is characterized by muscle weakness and fatigue, especially weakness of the muscles controlling eye and eyelid movement, facial expression, chewing and talking. In some cases the muscles controlling breathing are also affected, which can lead to respiratory failure that requires intubation and mechanical ventilation, known as a myasthenic crisis. The muscle weakness seen in myasthenia gravis is most often caused by circulating antibodies that mistakenly attack healthy tissue and inhibit normal neuromuscular transmission by blocking or damaging muscle receptor cells.

GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of myasthenia gravis in the 7MM, from 106,845 cases in 2014 to 119,939 cases in 2024, at an Annual Growth Rate (AGR) of 1.23% in the forecast period. The highest number of diagnosed prevalent cases of myasthenia gravis fell into the =75 year age group in the 7MM. The majority of diagnosed prevalent cases of myasthenia gravis in the 7MM in 2014 were women. The US and the 5EU markets follow a similar pattern, in which Class III has the highest number of diagnosed prevalent cases. Japan, however, has more cases in Class II than any other Class.

To build the epidemiological forecast of myasthenia gravis in the 7MM, GlobalData epidemiologists reviewed the literature and obtained country-specific, population-based studies that reported myasthenia gravis prevalence as determined via medical record reviews. GlobalData epidemiologists obtained country-specific diagnosed prevalence data for the US, Italy, the UK, and Japan, thereby providing valuable analysis of epidemiological trends amongst the 7MM. This forecast also includes age- and sex-specific segmentations, thereby providing detailed information about the characteristic of the disease in each market.

Scope

- The Myasthenia Gravis EpiCast Report provides an overview of the risk factors and global trends of myasthenia gravis in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of myasthenia gravis, segmented by sex, age, and Myasthenia Gravis Foundation of America (MGFA) classifications (Class I, Class II, Class III, Class IV, and Class V).
- The myasthenia gravis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Myasthenia Gravis EpiCast series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global myasthenia gravis market.
- Quantify patient populations in the global myasthenia gravis market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for myasthenia gravis therapeutics in each of the markets covered.
- Identify the percentage of myasthenia gravis prevalent cases by class.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaFocus: Tauopathies - Global Market Analysis

PharmaFocus: Tauopathies - Global Market Analysis

  • $ 9495
  • Industry report
  • February 2017
  • by GlobalData

PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...

Epiomic Epidemiology Series: Myasthemia Gravis Forecast in 26 Major Markets 2017-2027

Epiomic Epidemiology Series: Myasthemia Gravis Forecast in 26 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • April 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Myasthenia Gravis in 26 Major Markets Myasthenia Gravis (MG), also known as autoimmune myasthenia, is one of the most significant diseases ...

Epiomic Epidemiology Series: Bell’s Palsy Forecast in 15 Major Markets 2017-2027

Epiomic Epidemiology Series: Bell’s Palsy Forecast in 15 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • February 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Bell’s palsy in 15 Major Markets Bell's palsy, also known as idiopathic facial nerve palsy, is a weakness of the muscles on one side ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.